IP Chemo Shows Survival Benefit
Two studies recently released show a survival benefit for intraperitoneal IP chemotherapy
- Women with the BRCA1 mutation given IP chemotherapy survived three years longer than those given IV chemotherapy. Read an article about the study here.
- A study presented at the SGO Annual Meeting showed an improvement in median survival of 10 months. The abstracts can be found on p.56 here.